Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

Standardized and Individualized Parenteral Nutrition Mixtures in a Pediatric Home Parenteral Nutrition Population.

Nagelkerke SCJ, Jonkers-Schuitema CF, Kastelijn WLM, Gerards AE, Benninga MA, de Koning BAE, Tabbers MM.

J Pediatr Gastroenterol Nutr. 2019 Oct 23. doi: 10.1097/MPG.0000000000002528. [Epub ahead of print]

PMID:
31651804
2.

Genetic Variation in Low-To-Medium-Affinity Fcγ Receptors: Functional Consequences, Disease Associations, and Opportunities for Personalized Medicine.

Nagelkerke SQ, Schmidt DE, de Haas M, Kuijpers TW.

Front Immunol. 2019 Oct 3;10:2237. doi: 10.3389/fimmu.2019.02237. eCollection 2019. Review.

3.

Reporting on outcome measures in pediatric chronic intestinal failure: A systematic review.

Nagelkerke SCJ, Mager DJ, Benninga MA, Tabbers MM.

Clin Nutr. 2019 Sep 10. pii: S0261-5614(19)33039-0. doi: 10.1016/j.clnu.2019.08.027. [Epub ahead of print] Review.

PMID:
31551169
4.

Transient and chronic childhood immune thrombocytopenia are distinctly affected by Fc-γ receptor polymorphisms.

Schmidt DE, Heitink-Pollé KMJ, Laarhoven AG, Bruin MCA, Veldhuisen B, Nagelkerke SQ, Kuijpers TW, Porcelijn L, van der Schoot CE, Vidarsson G, de Haas M.

Blood Adv. 2019 Jul 9;3(13):2003-2012. doi: 10.1182/bloodadvances.2019000068.

5.

Extensive Ethnic Variation and Linkage Disequilibrium at the FCGR2/3 Locus: Different Genetic Associations Revealed in Kawasaki Disease.

Nagelkerke SQ, Tacke CE, Breunis WB, Tanck MWT, Geissler J, Png E, Hoang LT, van der Heijden J, Naim ANM, Yeung RSM, Levin ML, Wright VJ, Burgner DP, Ponsonby AL, Ellis JA, Cimaz R, Shimizu C, Burns JC, Fijnvandraat K, van der Schoot CE, van den Berg TK, de Boer M, Davila S, Hibberd ML, Kuijpers TW; International Kawasaki Disease Genetics Consortium.

Front Immunol. 2019 Mar 21;10:185. doi: 10.3389/fimmu.2019.00185. eCollection 2019.

6.

FcγRIIIb Restricts Antibody-Dependent Destruction of Cancer Cells by Human Neutrophils.

Treffers LW, van Houdt M, Bruggeman CW, Heineke MH, Zhao XW, van der Heijden J, Nagelkerke SQ, Verkuijlen PJJH, Geissler J, Lissenberg-Thunnissen S, Valerius T, Peipp M, Franke K, van Bruggen R, Kuijpers TW, van Egmond M, Vidarsson G, Matlung HL, van den Berg TK.

Front Immunol. 2019 Jan 30;9:3124. doi: 10.3389/fimmu.2018.03124. eCollection 2018.

7.

Pharmacological treatments for functional nausea and functional dyspepsia in children: a systematic review.

Browne PD, Nagelkerke SCJ, van Etten-Jamaludin FS, Benninga MA, Tabbers MM.

Expert Rev Clin Pharmacol. 2018 Dec;11(12):1195-1208. doi: 10.1080/17512433.2018.1540298. Epub 2018 Dec 6. Review.

PMID:
30360666
8.

Red pulp macrophages in the human spleen are a distinct cell population with a unique expression of Fc-γ receptors.

Nagelkerke SQ, Bruggeman CW, den Haan JMM, Mul EPJ, van den Berg TK, van Bruggen R, Kuijpers TW.

Blood Adv. 2018 Apr 24;2(8):941-953. doi: 10.1182/bloodadvances.2017015008.

9.

Genetic variation of human neutrophil Fcγ receptors and SIRPα in antibody-dependent cellular cytotoxicity towards cancer cells.

Treffers LW, Zhao XW, van der Heijden J, Nagelkerke SQ, van Rees DJ, Gonzalez P, Geissler J, Verkuijlen P, van Houdt M, de Boer M, Kuijpers TW, van den Berg TK, Matlung HL.

Eur J Immunol. 2018 Feb;48(2):344-354. doi: 10.1002/eji.201747215. Epub 2017 Nov 2.

10.

Nonclassical FCGR2C haplotype is associated with protection from red blood cell alloimmunization in sickle cell disease.

Meinderts SM, Sins JWR, Fijnvandraat K, Nagelkerke SQ, Geissler J, Tanck MW, Bruggeman C, Biemond BJ, Rijneveld AW, Kerkhoffs JH, Pakdaman S, Habibi A, van Bruggen R, Kuijpers TW, Pirenne F, van den Berg TK.

Blood. 2017 Nov 9;130(19):2121-2130. doi: 10.1182/blood-2017-05-784876. Epub 2017 Sep 12.

PMID:
28899854
11.

Enhanced Effector Functions Due to Antibody Defucosylation Depend on the Effector Cell Fcγ Receptor Profile.

Bruggeman CW, Dekkers G, Bentlage AEH, Treffers LW, Nagelkerke SQ, Lissenberg-Thunnissen S, Koeleman CAM, Wuhrer M, van den Berg TK, Rispens T, Vidarsson G, Kuijpers TW.

J Immunol. 2017 Jul 1;199(1):204-211. doi: 10.4049/jimmunol.1700116. Epub 2017 May 31.

12.

RhIg-prophylaxis is not influenced by FCGR2/3 polymorphisms involved in red blood cell clearance.

Stegmann TC, Veldhuisen B, Nagelkerke SQ, Winkelhorst D, Schonewille H, Verduin EP, Kuijpers TW, de Haas M, Vidarsson G, van der Schoot CE.

Blood. 2017 Feb 23;129(8):1045-1048. doi: 10.1182/blood-2016-05-716365. Epub 2017 Jan 12. No abstract available.

PMID:
28082442
13.

Correction: Evaluation of High-Throughput Genomic Assays for the Fc Gamma Receptor Locus.

Hargreaves CE, Iriyama C, Rose-Zerilli MJ, Nagelkerke SQ, Hussain K, Ganderton R, Lee C, Machado LR, Hollox EJ, Parker H, Latham KV, Kuijpers TW, Potter KN, Coupland SE, Davies A, Stackpole M, Oates M, Pettitt AR, Glennie MJ, Cragg MS, Strefford JC.

PLoS One. 2016 Mar 23;11(3):e0145040. doi: 10.1371/journal.pone.0145040. eCollection 2016. No abstract available.

14.

Fc-gamma receptor polymorphisms differentially influence susceptibility to systemic lupus erythematosus and lupus nephritis.

Tsang-A-Sjoe MW, Nagelkerke SQ, Bultink IE, Geissler J, Tanck MW, Tacke CE, Ellis JA, Zenz W, Bijl M, Berden JH, de Leeuw K, Derksen RH, Kuijpers TW, Voskuyl AE.

Rheumatology (Oxford). 2016 May;55(5):939-48. doi: 10.1093/rheumatology/kev433. Epub 2016 Jan 8.

PMID:
26748351
15.

Evaluation of High-Throughput Genomic Assays for the Fc Gamma Receptor Locus.

Hargreaves CE, Iriyama C, Rose-Zerilli MJ, Nagelkerke SQ, Hussain K, Ganderton R, Lee C, Machado LR, Hollox EJ, Parker H, Latham KV, Kuijpers TW, Potter KN, Coupland SE, Davies A, Stackpole M, Oates M, Pettitt AR, Glennie MJ, Cragg MS, Strefford JC.

PLoS One. 2015 Nov 6;10(11):e0142379. doi: 10.1371/journal.pone.0142379. eCollection 2015. Erratum in: PLoS One. 2016;11(3):e0145040.

16.

Simultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell Killing.

Brandsma AM, Ten Broeke T, Nederend M, Meulenbroek LA, van Tetering G, Meyer S, Jansen JH, Beltrán Buitrago MA, Nagelkerke SQ, Németh I, Ubink R, Rouwendal G, Lohse S, Valerius T, Leusen JH, Boross P.

Cancer Immunol Res. 2015 Dec;3(12):1316-24. doi: 10.1158/2326-6066.CIR-15-0099-T. Epub 2015 Sep 25.

17.

Nonallelic homologous recombination of the FCGR2/3 locus results in copy number variation and novel chimeric FCGR2 genes with aberrant functional expression.

Nagelkerke SQ, Tacke CE, Breunis WB, Geissler J, Sins JW, Appelhof B, van den Berg TK, de Boer M, Kuijpers TW.

Genes Immun. 2015 Sep;16(6):422-9. doi: 10.1038/gene.2015.25. Epub 2015 Jul 2.

PMID:
26133275
18.

Immunomodulation by IVIg and the Role of Fc-Gamma Receptors: Classic Mechanisms of Action after all?

Nagelkerke SQ, Kuijpers TW.

Front Immunol. 2015 Jan 21;5:674. doi: 10.3389/fimmu.2014.00674. eCollection 2014. Review.

19.

Inhibition of FcγR-mediated phagocytosis by IVIg is independent of IgG-Fc sialylation and FcγRIIb in human macrophages.

Nagelkerke SQ, Dekkers G, Kustiawan I, van de Bovenkamp FS, Geissler J, Plomp R, Wuhrer M, Vidarsson G, Rispens T, van den Berg TK, Kuijpers TW.

Blood. 2014 Dec 11;124(25):3709-18. doi: 10.1182/blood-2014-05-576835. Epub 2014 Oct 28.

PMID:
25352126
20.

FcγRIIa cross-talk with TLRs, IL-1R, and IFNγR selectively modulates cytokine production in human myeloid cells.

Vogelpoel LT, Hansen IS, Visser MW, Nagelkerke SQ, Kuijpers TW, Kapsenberg ML, de Jong EC, den Dunnen J.

Immunobiology. 2015 Feb;220(2):193-9. doi: 10.1016/j.imbio.2014.07.016. Epub 2014 Jul 25.

PMID:
25108563

Supplemental Content

Loading ...
Support Center